SDGR News and Press, Schrodinger Inc. From 02/11/26

Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “...

2026-02-03 15:06:17 ET More on OpenAI, Recursion and Absci Absci Corporation: Drawing Potential Insights On ABS-101 And ABS-201 Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript Absci Corporation (ABSI) Presents at 44...

AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift Canada NewsWire Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC , Jan. 29, 2026 /CNW/ --  Equity-Insider.com  News Commentary  – The global AI medical ...

Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular dis...

2026-01-09 09:15:47 ET More on Schrödinger, Eli Lilly, etc. Eli Lilly's 2026 Resolution: Volume Is The New Price Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why Eli Lilly ...

2026-01-09 08:33:44 ET More on Schrödinger, Eli Lilly Eli Lilly's 2026 Resolution: Volume Is The New Price Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why Lilly trial find...

Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be...

2026-01-07 02:15:03 ET UBS analyst issues NEUTRAL recommendation for SDGR on January 7, 2026 06:02AM ET. SDGR was trading at $18.79 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 7 - Buy, 3 - Hold recomm...

2026-01-07 02:05:29 ET Michael Yee from UBS issued a price target of $18.00 for SDGR on 2026-01-07 06:02:00. The adjusted price target was set to $18.00. At the time of the announcement, SDGR was trading at $18.79. The overall price target consensus is at $19.00 with hig...

2025-12-22 06:30:23 ET More on ARK Invest ARKK: Heads You Don't Win, Tails You Lose QQQ Vs. ARKK: The Critical Role Of Equity Duration In Growth Investing ARKX: Aerospace And Defense Are Set Up For High Growth In 2026 Cathie Wood buys the dip: Ark Invest load...